FDA OKs Enfortumab Vedotin Plus Pembro for Urothelial Cancer FDA OKs Enfortumab Vedotin Plus Pembro for Urothelial Cancer

The combination is the first approved alternative to first-line chemotherapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news